http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2797141-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fc779fa383ceb7941d1b8e54a5ff6527
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-107
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1075
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-57
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-107
filingDate 2011-04-26-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c73888b6a25a1abc59b38ba28452d192
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3449c044e635e07efa12b23a525220c7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_275295069de82440022c2709b62991fc
publicationDate 2011-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CA-2797141-A1
titleOfInvention Pharmaceutical emulsion compositions comprising progestogen
abstract The invention relates to a sterile, ready-to-use, pharmaceutical oil-in water emulsion composition for parenteral administration comprising: 0.015 to 1.2% wt./vol. of progestogen; 0.5-30% wt./vol.oil, wherein the oil comprises at least 85% wt.wt. triglyceride; 0.0425- 12.5% wt./vol phospholipid; 61.4-99.4%) wt./vol. aqueous medium; wherein the phospholipid is present in an amount of 6.8% - 43% of the oil (wt./wt.), and wherein the progestogen is present in an amount greater than or equal to 2.1wt% of the oil, preferably greater than or equal to 2.2wt% of the oil. The invention further relates to the use of the aforementioned composition in therapeutic or prophylactic treatment, said treatment comprising intravenous administration of the pharmaceutical composition.
priorityDate 2010-04-26-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419487093
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID134688829
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419483452
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415122724
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID445639
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID962
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5460221
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2345
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5994
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID433323226
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419512635
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419553937
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID456986878
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID753

Total number of triples: 37.